Sun Pharma Advanced Research Co (BOM:532872) ROCE %: 500.46% (As of Mar. 2026)


BOM:532872 Sun Pharma Advanced Research Co Ltd BOM:532872
57 GF Score
Price ₹237.55
GF Value ₹4,486.49
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Sun Pharma Advanced Research Co ROCE %?

Sun Pharma Advanced Research Co BOM:532872 +1.26% 57 ROCE % is 500.46% as of Mar. 2026. GuruFocus rates BOM:532872 with a GF Score™ of 57/100 and a GF Value™ of ₹4,486.49 (Possible Value Trap). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sun Pharma Advanced Research Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 500.46%.

Sun Pharma Advanced Research Co  (BOM:532872) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sun Pharma Advanced Research Co ROCE % Related Terms

Sun Pharma Advanced Research Co ROCE % Historical Data

* Premium members only.

The historical data trend for Sun Pharma Advanced Research Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sun Pharma Advanced Research Co ROCE % Chart

Sun Pharma Advanced Research Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -362.06 -56.58 -85.59 -315.93 230.34

Sun Pharma Advanced Research Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 500.46
BOM:532872
57GF Score
Sun Pharma Advanced Research Co Ltd BOM:532872
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sun Pharma Advanced Research Co ROCE % Calculation

Sun Pharma Advanced Research Co's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=15871.4/( ( (3355.335 - 3742.403) + (21708.6 - 7540.9) )/ 2 )
=15871.4/( (-387.068+14167.7)/ 2 )
=15871.4/6890.316
=230.34 %

Sun Pharma Advanced Research Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=70904/( ( (0 - 0) + (21708.6 - 7540.9) )/ 1 )
=70904/( ( 0 + 14167.7 )/ 1 )
=70904/14167.7
=500.46 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 500.46% mean?
Sun Pharma Advanced Research Co (BOM:532872) has a ROCE % of 500.46% as of Mar. 2026.
Is Sun Pharma Advanced Research Co's ROCE % too high?
Sun Pharma Advanced Research Co's current ROCE % is 500.46%. The Drug Manufacturers industry median ROCE % is 7.03. Sun Pharma Advanced Research Co's value of 500.46% is 7018.9% above this industry median. Overall, Sun Pharma Advanced Research Co has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sun Pharma Advanced Research Co's ROCE % compare to ZTS and UTHR?
Sun Pharma Advanced Research Co's ROCE % of 500.46% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Sun Pharma Advanced Research Co's value of 500.46% is 7018.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sun Pharma Advanced Research Co's current ROCE % of 500.46% is 7018.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sun Pharma Advanced Research Co's current ROCE % is 500.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sun Pharma Advanced Research Co stock overvalued right now?
Based on GuruFocus' analysis, Sun Pharma Advanced Research Co (BOM:532872) is currently considered Possible Value Trap. The stock's GF Value™ is ₹4,486.49, compared to a current price of ₹237.55 — trading 94.7% below its estimated fair value. The current ROCE % is 500.46% and 7018.9% above the Drug Manufacturers industry median of 7.03. Sun Pharma Advanced Research Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sun Pharma Advanced Research Co (BOM:532872), the current ROCE % is 500.46% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sun Pharma Advanced Research Co (BOM:532872) Overvalued in 2026?

Based on GuruFocus' analysis, Sun Pharma Advanced Research Co stock appears to be undervalued. The current stock price of ₹237.55 is trading 94.7% below its estimated GF Value™ of ₹4,486.49. GuruFocus considers Sun Pharma Advanced Research Co to be Possible Value Trap.

Key valuation signals for BOM:532872:

  • ROCE %: 500.46%
  • GF Value™: ₹4,486.49 vs. price of ₹237.55 (94.7% below fair value)
  • GF Score™: 57/100 with 7 warning signs
  • Industry Position: 7018.9% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:532872 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sun Pharma Advanced Research Co Business Description

Other Exchanges SPARC:India
Address Off Mahakali Caves Road, 17-B, Mahal Industrial Estate, Andheri (East), Mumbai, MH, IND, 400093
Sun Pharma Advanced Research Co Ltd is an Indian specialty and generic drug manufacturing company. The company has identified pharmaceuticals research and development as its only reportable segment. The company is focused on drug discovery in focused therapy areas such as cancer and anti-inflammatory treatments. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. It derives maximum revenue from India and also has its presence in other countries.
57GF Score

Get the complete analysis for BOM:532872

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹237.55
Price
₹4,486.49
GF Value